Gene Therapy for Huntington’s Disease


Volume

Reagent

Final concentration

Complete DMEM media

500 mL

DMEM (Invitrogen #12430-062)
 
50 mL

Fetal bovine serum (Thermo HyClone #SH30406.02)

9 %

5 mL

Non-essential amino acids (100×, Invitrogen, #11140050)

0.9 %

5 mL

Sodium pyruvate (100×, Invitrogen, #11360-070)

0.9 %

IMDM media

500 mL

IMDM (Invitrogen, #12440-061)
 
25 mL

Fetal bovine serum (Thermo HyClone #SH30406.02)

5 %

10× PBS

4 g

KH2PO4

15 mM

23 g

Na2HPO4

81 mM

160 g

NaCl

1.37 M

4 g

KCl

27 mM

Make up to 2 L with ultrapure water. Dilute 10× PBS stock to make 1× PBS, adjust pH to 7.4, and filter sterilize

2× HeBs buffer

23.83 g

HEPES

50 mM

32.73 g

NaCl

280 mM

0.426 g

Na2HPO4

1.5 mM

Dissolve in 1,800 mL ultrapure water, adjust pH to 7.05, and make up to final volume of 2 L. Filter sterilize and store in aliquots at −20 °C (see Note 1)

2.5 M CaCl 2

Dissolve 36.75 g CaCl2 in ~80 mL of ultrapure water and make up to 100 mL. Filter sterilize and store in aliquots at −20 °C





2.2 Purification of rAAV Vectors



2.2.1 Cell Lysis


See Table 2


Table 2
Solutions and reagents






















































Solutions

Volume

Reagent

Final concentration

Lysis bufferheparin

15 mL

5 M NaCl

150 mM

10 mL

1 M Tris, pH 8

 20 mM

Make up to a final volume of 500 mL with ultrapure water and adjust pH to 8 with HCl. Filter sterilize and store at 4 °C

Lysis bufferiodixanol

7.5 mL

5 M NaCl

150 mM

10 mL

1 M Tris, pH 8.5

 50 mM

Make up to a final volume of 250 mL with ultrapure water and adjust pH to 8.5 with HCl. Filter sterilize and store at 4 °C

10 % sodium deoxycholate

0.5 g

Sodium deoxycholate (Sigma, #D6750)

10 %

Dissolve in ultrapure water to a final volume of 5 mL and filter sterilize. Prepare fresh solution as required

Reagent

Supplier

Item number

Benzonase

Sigma

E1014-25KU


2.2.2 Heparin Column Purification


See Table 3


Table 3
Solutions and reagents










































































Solutions

Heparin column purification buffers
 
5 M NaCl (mL)

1 M Tris, pH 8 (mL)

Final volume (mL)

100 mM NaCl, 20 mM Tris, pH 8

10

10

500

200 mM NaCl, 20 mM Tris, pH 8

2

1

50

300 mM NaCl, 20 mM Tris, pH 8

3

1

50

400 mM NaCl, 20 mM Tris, pH 8

4

1

50

450 mM NaCl, 20 mM Tris, pH 8

4.5

1

50

500 mM NaCl, 20 mM Tris, pH 8

5

1

50

Add required amount of 5 M NaCl and 1 M Tris, make up to a final volume with ultrapure water, and adjust pH to 8 with HCl. Filter sterilize and store at 4 °C

10× PBSMK

Dissolve 0.2 g MgCl2 · 6H2O in 100 mL 10× PBS. Filter sterilize and store at room temperature. Dilute 10× stock to 1× PBS-MK with ultrapure water where required, filter sterilize, and store at 4 °C

1 % pluronic acid

Dissolve 0.5 g Pluronic F68 (Fluka, #81112) in 50 mL ultrapure water. Filter sterilize and store at 4 °C. Add to 1× PBS-MK to a final concentration of 0.001 %

Reagent

Supplier

Item number

HiTrap® Heparin Cartridge

Sigma

54836

Amicon Ultra 4 100K MWCO centrifugal filter units

Millipore

UFC810024

Acrodisc syringe filters 13 mm 0.2 μm Tuffryn

Pall

4454


2.2.3 Iodixanol Purification


See Table 4


Table 4
Solutions and reagents






















































































Volume

Reagent

Final concentration

2 M NaCl in 1× PBSMK

5 mL

10× PBS-MK


20 mL

5 M NaCl

2 M

Make up to a final volume of 50 mL with ultrapure water. Filter sterilize and store at 4 °C

54 % iodixanol

40.5 mL

OptiPrep (Sigma, #D1556)

54 %

4.5 mL

10× PBS-MK


Filter using a 0.45 μm syringe filter and store at 4 °C

40 % iodixanol

11.2 mL

54 % iodixanol

40 %

3.9 mL

1× PBS-MK


25 % iodixanol

7 mL

54 % iodixanol

25 %

8.1 mL

1× PBS-MK


15 % iodixanol

6 mL

54 % iodixanol

6 %

4.8 mL

1× PBS-MK


10.8 mL

2 M NaCl in 1× PBS-MK

1 M

Reagent

Supplier

Item number

35 mL Sorvall Ultracrimp tube

Thermo Scientific

03989

Amicon Ultra 15 100K MWCO centrifugal filter units

Millipore

UFC901008

Spinal needles

Becton Dickinson

405248


2.3 Titration of rAAV Vectors


See Table 5


Table 5
Reagents



































Reagent

Supplier

Item number

DNase I

New England Biolabs

B0303S

DNase I reaction buffer (10×)

New England Biolabs

M0303S

Proteinase K

Roche

03115887001

Power SYBR Green PCR master mix

Applied Biosystems

4367659

Custom oligonucleotides

Invitrogen

GGC-TGT-TGG-GCA-CTG-ACA-AT

CCG-AAG-GGA-CGT-AGC-AGA-A

Forward WPRE primer

Reverse WPRE primer



3 Methods



3.1 rAAV Vector Packaging


This section describes procedures for packaging AAV vectors. The expression plasmid expresses a transgene under control of a constitutive or cell-specific promoter flanked by AAV2 inverted terminal repeats. AAV serotype is determined by the inclusion of the appropriate AAV plasmid expression serotype-specific capsid proteins.

Our standard preparation of AAV vector typically yields ~300 μL of AAV vector of 1012–1013 vector genomes/mL from 5 × 15 cm tissue culture plates.


3.1.1 HEK293 Cell Culture


Human embryonic kidney 293 (HEK293) cells (low passage HEK293 cells, Microbix Biosystems Inc., Ontario, Canada) are cultured in complete DMEM in T175 cm2 tissue culture flasks.


3.1.2 Transfection of HEK293 Cells




1.

For each batch of rAAV vector, HEK293 cells are seeded into 5 × 15 cm diameter tissue culture plates in 25 mL complete DMEM. The number of cells in one fully confluent T175 flask is sufficient to seed 3.5–3.75 15 cm plates, such that the plates are 70 % confluent at the time of transfection (see Notes 2 and 3).

 

2.

The following day, 3 h prior to transfection, remove the media from each plate and replace with 25 mL IMDM.

 

3.

Bring transfection reagents to room temperature, and immediately prior to transfection, prepare the DNA mix in a 50 mL tube as follows:

For chimeric AAV1:2 vectors



  • 12 mL ultrapure water


  • 1.65 mL 2.5 M CaCl2


  • 62.5 μg pAAV expression plasmid


  • 125 μg pFdelta6 (adenovirus helper plasmid)


  • 30 μg pNLrep (AAV2 helper)


  • 31.25 μg pH21 (AAV1 capsid)


For AAV vectors (any serotype)



  • 12 mL ultrapure water


  • 1.65 mL 2.5 M CaCl2


  • 62.5 μg pAAV expression plasmid (AAV cis plasmid)


  • 125 μg pFdelta6 (adenovirus helper plasmid)


  • 61.25 μg pAAV capsid plasmid (see Note 4)

 

4.

Sterilize the DNA mix by filtration through a 0.2 μm Acrodisc syringe filter into a 75 cm2 tissue culture flask.

 

5.

For the transfection, whilst vortexing the DNA mix vigorously, add 13 mL of 2× HeBS buffer. The combined mixture is vortexed for a further 10–15 s and then left to stand at room temperature for a further 1 min and 45 s (see Notes 5 and 6).

 

6.

Gently pipette 5 mL of the transfection mix into each 15 cm plate of HEK293 cells in IMDM in a circular dropwise motion. Agitate the plates to ensure adequate distribution of transfection mix and return the plates to the tissue culture incubator.

 

7.

Sixteen hours later, remove the media and replace with 25 mL fresh prewarmed (37 °C) complete DMEM and return plates to the incubator.

 

8.

Sixty hours after transfection, harvest the HEK293 cells as follows: remove the media and gently pipette ~25 mL prewarmed 1× PBS, swirl the plate gently, and remove the PBS and discard. Add 25 mL 1× PBS and detach the cells from the plate using a cell scraper and collect in sterile 50 mL tubes.

 

9.

The cells are pelleted by centrifugation at 600 × g for 30 min in a centrifuge equipped with a swing-out rotor. Discard the supernatant and proceed to Sects. 3.1.3 or 3.1.4.

 


3.1.3 Purification of rAAV Vectors: Heparin Column Purification for Chimeric AAV1:2 Vectors


This purification method is suitable for the purification of AAV serotype 2 or chimeric AAV1:2 vectors only:

1.

From Sect. 3.1.2, resuspend the cell pellets in 50 mL 150 mM NaCl, 20 mM Tris–HCl pH 8.0. Split into two 25 mL aliquots in 50 mL tubes, and store overnight at −20 °C or continue on to step 2.

 

2.

Thaw the two 25 mL aliquots of cell lysate, and add sodium deoxycholate to a final concentration of 0.5 % (1.25 mL of 10 % (w/v) sodium deoxycholate) and Benzonase to a final concentration of 50 U/mL.

 

3.

After mixing thoroughly, incubate the tubes in a 37 °C water bath for 1 h. Vortex the tubes every 15 min during the incubation period.

 

4.

Centrifuge the tubes at 3,000 × g for 15 min, and pool the supernatants into a fresh 50 mL tube before storing overnight at −20 °C prior to heparin column purification.

 

5.

Thaw the supernatants and centrifuge at 4,000 × g for 15 min to remove any protein precipitate.

 

6.

Pre-equilibrate a 1 mL Hi-Trap heparin HP column with 15 mL 150 mM NaCl, 20 mM Tris–HCl pH 8.0, using a Harvard infusion pump at a flow rate of 1 mL/min and a disposable 60 mL syringe. Load the cell supernatant into the 60 mL syringe and load the sample onto the heparin column.

 

7.

Wash the column with 30 mL 100 mM NaCl, 20 mM Tris–HCl pH 8.0.

 

8.

Remove the column from the infusion pump and manually elute from the column into separate tubes at a rate of 1 mL/min using 1–5 mL disposable syringes with the following buffers:



  • 1 mL 200 mM NaCl, 20 mM Tris–HCl pH 8.0


  • 1 mL 300 mM NaCl, 20 mM Tris–HCl pH 8.0


  • 1.5 mL 400 mM NaCl, 20 mM Tris–HCl pH 8.0


  • 3 mL 450 mM NaCl, 20 mM Tris–HCl pH 8.0


  • 1.5 mL 500 mM NaCl, 20 mM Tris–HCl pH 8.0

 

9.

Pool the 400–500 mM NaCl, 20 mM Tris–HCl pH 8.0 fractions, and transfer to a 4 mL 100K MWCO Amicon centrifugal concentrator.

 

10.

Centrifuge at 3,400 × g at 4 °C to a volume of ~100–200 μL. Add 4 mL 1× PBS-MK containing 0.001 % pluronic acid to the concentrator, and centrifuge sample to a volume of ~100–200 μL. Perform a second wash step with 4 mL 1× PBS-MK containing 0.001 % pluronic acid, and concentrate the sample to a volume of ~150 μL.

 

11.

Transfer the sample to a sterile 1.5 mL tube. To ensure all the rAAV is retrieved, rinse the concentrator with a further 150–200 μL of 1× PBS-MK, and pool this sample with the first 150 μL sample.

 

12.

The rAAV vector stock (~350 μL) is then filter sterilized through a 13 mm 0.2 μm low-protein binding Acrodisc filter into a fresh sterile 1.5 mL tube (final volume ~300 μL).

 

13.

Aliquot the vector and store at −80 °C.

 


3.1.4 Iodixanol Purification Method for All AAV Serotypes


This method is suitable for the purification for all AAV serotypes and as an alternative purification method for serotype 2 or chimeric AAV1:2 vectors:



1.

From Sect. 3.1.2, resuspend the cell pellet to a final volume of 8 mL in lysis buffer (150 mM NaCl, 50 mM Tris–HCl pH 8.5). The lysate can be frozen at this stage or following the next deoxycholate/Benzonase step.

 

2.

Add sodium deoxycholate to a final concentration of 0.5 % (400 μL of 10 % (w/v) sodium deoxycholate in 8 mL) and Benzonase to a final concentration of 50 U/mL. Mix well and incubate in a 37 °C water bath for 60 min. Vortex the tubes every 15 min during the incubation period.

 

3.

Centrifuge the lysate at 3,000 × g for 30 min using a fixed angle rotor. Transfer the supernatant into a clean tube and freeze samples at −20 °C.

 

4.

The following day, thaw cell lysates and centrifuge at 5,000 × g for 30 min before transferring the supernatant to a fresh tube.

 

5.

Set up the gradient in a disposable 35 mL ultracentrifuge tube. We use Sorvall Ultracrimp tubes and sealing system. Load the gradient in the following order using a spinal needle attached to a 10 mL disposable syringe. Hold the needle against the side of the tube and slowly expel each solution so as to not disturb the layer above.



  • 7.5–8.0 mL of cell lysate


  • 8.5 mL 15 % iodixanol


  • 6.0 mL 25 % iodixanol


  • 5.0 mL 40 % iodixanol


  • 5.0 mL 54 % iodixanol

 

6.

Very carefully add lysis buffer to the cell lysate (at the top of the tube) to within 1–2 mm below the bottom of the plastic stopper. Weigh each tube and lid (plastic stopper and cap) and tube adapter.

 

7.

Generate another tube in a similar manner with another sample or lysis buffer to act as a balance for ultracentrifugation. Once pairs of tubes are generated, insert stopper, metal cap, and crimp the tube. Place a pen mark at the 40–54 % iodixanol interface to aid identification for sample retrieval following centrifugation.

 

8.

Place tubes in Sorvall ultracentrifuge T865 rotor and centrifuge at 58,000 rpm for 1 h and 45 min. This will include a 15 min acceleration and 90 min spin. Remove tubes carefully from rotor.

 

9.

In a tissue culture hood, place the tube in a clamp stand. Insert an 18 G needle attached to a 5 mL syringe at the 40–54 % iodixanol interface. Insert a 21 G needle at the top of the tube to facilitate entry of air into the tube. With the bevel of the needle facing upwards, carefully draw off 3.5 mL of the 40 % iodixanol layer containing vector and transfer this to a 50 mL tube.

 

10.

Add 10 mL of 1× PBS-MK containing 0.001 % pluronic acid to the vector sample, and load into a 15 mL 100 kDa molecular weight cut-off Amicon concentrator. Centrifuge at 3,400 × g until the volume is reduced to ~200 μL. Add 14–15 mL 1× PBS-MK with pluronic acid and centrifuge as above. Repeat 2–3 times until the iodixanol is removed. When adding the wash buffer, gently pipette the sample up and down to determine whether iodixanol is present.

 

Sep 24, 2016 | Posted by in NEUROLOGY | Comments Off on Gene Therapy for Huntington’s Disease

Full access? Get Clinical Tree

Get Clinical Tree app for offline access